Common adverse effects of breast cancer chemotherapy
Traditional chemotherapy plays an important role in the treatment of breast cancer, where the most common chemotherapy drugs for breast cancer include: cystals, violets, long-chronic Ribbon, platinum, anti- metabolic drugs, cyclophosphorous amide, etc., which can lead to adverse effects such as bone marrow inhibition, digestive tract reaction, and hair loss. Bone marrow inhibition is the most common side effect of chemotherapy. The marrow inhibition not only affects the efficacy of treatment by delaying chemotherapy but can also lead to complications that endanger the life of the patient.
Chemopharmaceutical drugs cause hair loss, which is most likely to occur after 2 to 3 weeks after the start of chemotherapy, in the ring, cyclophosphodomide, violet and long spring alkalis. The use of lipid-packed drugs by those who are in a position to do so may reduce the loss of hair. When the hair is removed, care should be taken with regard to headscarf care, preferably with soft hats or silk towels, with a soft cleaning of the headscarf, and with a minimum of friction, sun and so forth. The withdrawals from chemotherapy are generally reversible and begin to regenerate after a period of 1-2 months. Disgusting, vomiting is the most common early toxic response to chemotherapy, and severe vomiting can even prevent the patient from eating, followed by dehydration, electrolytic disorders, etc. Spraying due to chemotherapy can be classified as acute vomiting (24 hours of chemotherapy) and delayed vomiting (1 week after chemotherapy). Programmes that contain platinum (especially platinum) and cylindrical (polyser) drugs cause more disgusting and vomiting. Young patients are more vulnerable to vomiting and vomiting than older patients. Ear toxicity is a more specific toxic response for platinum, mainly in the form of ear ringing and high-frequency hearing reduction, with most reversible doses of treatment and no special treatment. It should be noted, however, that sauperium cannot be used for mid-earitis patients and cannot be shared with aminocin antibiotics (cystalcin, ginacin, etc.) in order to avoid irreversible deafness. A foot and foot syndrome is a dermal toxic reaction that can begin 11 to 360 days after the start of chemotherapy, mainly in areas under pressure of hand and foot, in the form of arm and foot numbness, sensory retardation, abnormality, sting, pain-freeness or pain, skin swelling or red spots, twitching, cracking, hard-line water bubbles or severe pain. The chance of a foot and foot syndrome is close to 50% when you take Capitabin.
